Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Annual Income Statement (USD)
AMRX Quarterly Financials (USD)
Frequently Asked Questions About Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Stock
Amneal Pharmaceuticals, Inc. Class A Common Stock's (AMRX) last reported annual revenue was USD 2.39 Billion.
Amneal Pharmaceuticals, Inc. Class A Common Stock's (AMRX) annual revenue growth rate based on the revenue reported in the past 5 years is : 7.56%
Amneal Pharmaceuticals, Inc. Class A Common Stock's(AMRX) is not profitable as of its last reported annual financials.
The net profit margin for Amneal Pharmaceuticals, Inc. Class A Common Stock's(AMRX) from its laster reported year is -3.51%
The return on equity (ROE) for Amneal Pharmaceuticals, Inc. Class A Common Stock's(AMRX) from its last reported annual financials is : -148.99%
The return on assets (ROA) for Amneal Pharmaceuticals, Inc. Class A Common Stock's(AMRX) from its last reported annual financials is : 6.09%
The return on invested capital (ROIC) for Amneal Pharmaceuticals, Inc. Class A Common Stock's(AMRX) from its last reported annual financials is : 7.09%
The Debt to Equity ratio for Amneal Pharmaceuticals, Inc. Class A Common Stock's(AMRX) from its last reported annual financials is : 12271.63%
The dividend yield for Amneal Pharmaceuticals, Inc. Class A Common Stock's(AMRX) from its laster reported year is 0.00%
Amneal Pharmaceuticals, Inc. Class A Common Stock's(AMRX) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AMRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
